




Innovative Medicines Initiative

The Innovative Medicines Initiative, Knowledge Management and Statistical Programming. What is the relationship?


Ann Marie Martin



Open Innovation: From Promise to Practise




- Linux, Wikipedia, Open Clinica are famous examples of open collaborations.
- P&G, Elli Lilly are using Innocentive – bounty hunter model.
- Companies are recognizing the value of open innovation and collaborative research under appropriate Intellectual Property models.
- The Innovative Medicines Initiative provides opportunities for collaborative research on innovation in drug development.




Innovative Medicines Initiative (IMI)



- A public-private partnership focused on needs common to pharmaceutical industry and patients
- Under the EU's 7th Research Framework Programme (€ 50 billion 2007-2013), Joint Technology Initiatives (JTI) have been introduced to realize public- private partnerships.
- IMI is a Joint Undertaking (JU) between the Pharmaceutical Industry (EFPIA) and the European Union (EC).
- Governance: Board, Executive Office, Scientific Committee as well Stakeholders Forum and Member States Group.
- Budget 2008-2017: € 2 billion (EU € 1 billion, private sector: at least € 1 billion of in-kind contributions, associated countries: CH, IS, ...).
- Lisbon Treaty (1 December 2009) further strengthens the European Research Area.



Organization of the Partnership



What does the IMI Executive Office do?


Enable the Implementation Strategic Research Agenda (SRA)

Projects in Efficacy, Safety, Knowledge Management, Education & Training


Call 2008: 15 projects – grants issued, projects started or starting

Call 2009: 8 call topics, Stage 1, 1st peer review

Call 2010: priorities prepared and under review




- provides the data pooling and data processing infrastructure to support IMI PPPs.
- Translational KM and KM platform
- Distributed/federated multilayer, service-oriented and ontology driven architecture.
- Gaps in data representation, exchange standards, ontology development, data protection, text mining → specific projects
- Addressing data interoperability.




KM projects - examples

- e-TOX – Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in-silico prediction of toxicities
- DDMLF - Drug Disease Modelling Library and Framework
- OPS - Open Pharmacological Space
- EHR - Electronic Health Records



Develop a database and novel software tools to better predict in-silico the tox profiles of new compounds in the early stages of drug development

- Largest tox database combining public and historical data from 14 companies
- Systems and tools to harmonize tox standards and terms (ontologies) as well as support data entry and compatibility
- Create a computer prediction system for potential toxicity of new compounds based on analysis of the above database
- Create meta-tool for simultaneous analysis of data of various origins and formats



Drug/Disease Modeling: Library and Framework (DDMLF)






Figure 1: Proposed framework concept diagram. Monolix, NONMEM, BUGS and S-Plus/R are commonly-used software tools in the pharmacometric domain.


Electronic Health Records (EHR)



Statistical Programming – what is the relationship?



- IMI is a public-private partnership focused on needs common to pharmaceutical industry and patients.
- One of those common needs in the pharma industry and patients is to create a clinical reporting system which is used widely and is easily maintainable.
- PhUSE has the opportunity to be 'the' partner of choice for regulatory agencies such as the FDA.
- An IMI project is the ideal setting for creating such a clinical reporting system by allowing :
 - Company personnel to work in a collaborative setting along with academics and SMEs
 - Provides development opportunities.
 - Come up with an efficient, up-to-date reporting system that establishes clear analysis rules endorsed by regulatory agencies.
- Up to you and your management to propose a project to your IMI contacts in your companies.




Participating Companies

- Amgen
- Astra Zeneca
- Bayer
- Boehringer Ingelheim
- Elli Lilly
- Esteve
- GSK
- J&J
- Lundbeck
- Merck
- Merck Serono
- Novartis
- Novo Nordisk
- Orion
- Pfizer
- Roche
- Sanofi Aventis
- Servier
- Sigma-Tau
- UCB
-

In Summary:


- Contributions in-kind
- Appropriate intellectual property
- Collaborative
- Innovative
- A public-private partnership focused on needs common to the pharmaceutical industry and patients



Thank YOU



- I cannot stay for the day....
- Not because I am not interested
- But because one of the evaluations is starting this afternoon
- On the PhUSE Board of Directors I represent Benelux, France, Germany, Skandinavia.
- I would like to invite you to send your suggestions for PhUSE to ann.martin@imi.europa.eu



Web 3...Knowledge Management

